Literature DB >> 10508049

In vitro susceptibilities of Mycoplasma hominis to six fluoroquinolones as determined by E test.

K B Waites1, K C Canupp, G E Kenny.   

Abstract

Twenty isolates of Mycoplasma hominis were tested for their susceptibility to six fluoroquinolones by the E test. The MICs at which 90% of the isolates were inhibited (in micrograms per milliliter) were as follows: sparfloxacin, 0.031; clinafloxacin, moxifloxacin, and trovafloxacin, 0.063; levofloxacin, 0.25; and ciprofloxacin, 0.5. Increasing the amount of inoculum or incubation in CO(2) elevated MICs by </=1 dilution. E tests produce fluoroquinolone MICs comparable to those obtained by agar and microbroth dilution for M. hominis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10508049      PMCID: PMC89525          DOI: 10.1128/AAC.43.10.2571

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  11 in total

1.  Susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum to a new quinolone, trovafloxacin (CP-99,219).

Authors:  G E Kenny; F D Cartwright
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

2.  In-vitro susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis and Ureaplasma urealyticum to clinafloxacin, PD 131628, ciprofloxacin and comparator drugs.

Authors:  M A Cohen; M D Huband
Journal:  J Antimicrob Chemother       Date:  1997-08       Impact factor: 5.790

3.  Increase in resistance of Mycoplasma hominis to tetracyclines.

Authors:  M C Cummings; W M McCormack
Journal:  Antimicrob Agents Chemother       Date:  1990-12       Impact factor: 5.191

4.  Susceptibilities of genital mycoplasmas to the newer quinolones as determined by the agar dilution method.

Authors:  G E Kenny; T M Hooton; M C Roberts; F D Cartwright; J Hoyt
Journal:  Antimicrob Agents Chemother       Date:  1989-01       Impact factor: 5.191

5.  Evaluation of the Etest for detection of tetracycline resistance in Mycoplasma hominis.

Authors:  K B Waites; D M Crabb; L B Duffy; G H Cassell
Journal:  Diagn Microbiol Infect Dis       Date:  1997-04       Impact factor: 2.803

6.  Susceptibilities of Mycoplasma hominis and Ureaplasma urealyticum to two new quinolones, sparfloxacin and WIN 57273.

Authors:  G E Kenny; F D Cartwright
Journal:  Antimicrob Agents Chemother       Date:  1991-07       Impact factor: 5.191

7.  In vitro susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum to sparfloxacin and PD 127391.

Authors:  K B Waites; L B Duffy; T Schmid; D Crabb; M S Pate; G H Cassell
Journal:  Antimicrob Agents Chemother       Date:  1991-06       Impact factor: 5.191

8.  Susceptibilities of Mycoplasma hominis, Mycoplasma pneumoniae, and Ureaplasma urealyticum to a new quinolone, OPC 17116.

Authors:  G E Kenny; F D Cartwright
Journal:  Antimicrob Agents Chemother       Date:  1993-08       Impact factor: 5.191

Review 9.  Extragenital Mycoplasma hominis infections in adults: emphasis on immunosuppression.

Authors:  R D Meyer; W Clough
Journal:  Clin Infect Dis       Date:  1993-08       Impact factor: 9.079

10.  Comparative in-vitro activity of sparfloxacin against genital pathogens.

Authors:  E J Perea; J Aznar; M C Garcia-Iglesias; A Pascual
Journal:  J Antimicrob Chemother       Date:  1996-05       Impact factor: 5.790

View more
  7 in total

Review 1.  The Brief Case: Mycoplasma hominis Extragenital Abscess.

Authors:  Sarah Stabler; Emmanuel Faure; Claire Duployez; Frédéric Wallet; Rodrigue Dessein; Rémi Le Guern
Journal:  J Clin Microbiol       Date:  2021-03-19       Impact factor: 5.948

2.  Comparative activities of telithromycin (HMR 3647), levofloxacin, and other antimicrobial agents against human mycoplasmas.

Authors:  C M Bebear; H Renaudin; A Bryskier; C Bebear
Journal:  Antimicrob Agents Chemother       Date:  2000-07       Impact factor: 5.191

Review 3.  Mycoplasma hominis, a Rare but True Cause of Infective Endocarditis.

Authors:  Amandine Gagneux-Brunon; Florence Grattard; Jerome Morel; Florence Suy; Jean-François Fuzellier; Paul Verhoeven; Celine Cazorla; Claire Guglielminotti; Anne Fresard; Frederic Lucht; Elisabeth Botelho-Nevers
Journal:  J Clin Microbiol       Date:  2015-07-01       Impact factor: 5.948

4.  A case of Mycoplasma hominis meningo-encephalitis in a full-term infant: rapid recovery after start of treatment with ciprofloxacin.

Authors:  Katja C Wolthers; René F Kornelisse; Gert J J M Platenkamp; M Inge Schuurman-van der Lem; Cindy van der Schee; Nico G Hartwig; Cees M Verduin
Journal:  Eur J Pediatr       Date:  2003-05-10       Impact factor: 3.183

5.  Comparative in vitro susceptibilities and bactericidal activities of investigational fluoroquinolone ABT-492 and other antimicrobial agents against human mycoplasmas and ureaplasmas.

Authors:  Ken B Waites; Donna M Crabb; Lynn B Duffy
Journal:  Antimicrob Agents Chemother       Date:  2003-12       Impact factor: 5.191

6.  In vitro susceptibilities to and bactericidal activities of garenoxacin (BMS-284756) and other antimicrobial agents against human mycoplasmas and ureaplasmas.

Authors:  Ken B Waites; Donna M Crabb; Xue Bing; Lynn B Duffy
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

7.  Mycoplasma hominis necrotizing pleuropneumonia in a previously healthy adolescent.

Authors:  Andres Pascual; Marie-Helene Perez; Katia Jaton; Gaudenz Hafen; Stefano Di Bernardo; Jacques Cotting; Gilbert Greub; Bernard Vaudaux
Journal:  BMC Infect Dis       Date:  2010-11-24       Impact factor: 3.090

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.